Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Enveric Biosciences Inc. - news published 259 - readings 4.280

BACK

Enveric Biosciences Inc.

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Key CMC achievements advance EB-003 on the path to first-in-human trials CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced significant progress in the chemistry, manufacturing ...

02.10.2025

Enveric Biosciences Inc.

Registration Statement - Specified Transactions (Form S-3)

As filed with the Securities and Exchange Commission on September 26, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enveric Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 95-4484725 (State or other jurisdiction of (I.R.S. Empl ...

29.09.2025

Enveric Biosciences Inc.

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds (Form 8-K)

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds CAMBRIDGE, Mass., September 17, 2025 - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into d ...

18.09.2025

Enveric Biosciences Inc.

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding series A warrants to purchase up to an aggregat ...

18.09.2025

Enveric Biosciences Inc.

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series A warrants to purchase up ...

17.09.2025

Enveric Biosciences Inc.

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Research published in ACS Chemical Biology and BioDesign Research describes new approaches for producing tryptamine and MDMA-derived compounds CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders ...

17.09.2025

Enveric Biosciences Inc.

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric expects to file Investigational New Drug application for EB-003 in early 2026 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has received a written response ...

16.09.2025

Enveric Biosciences Inc.

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global In ...

03.09.2025

Enveric Biosciences Inc.

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Move aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric an ...

02.09.2025

Enveric Biosciences Inc.

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA (Form 8-K)

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA Move aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 CAMBRIDGE, Mass., September 2, 2025 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology com ...

02.09.2025

Enveric Biosciences Inc.

Regulation FD Presentation (Form 8-K)

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Enveric Biosciences Inc. published this content on August 29, 2025 , and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT) , unedited and unaltered, on August 29, 2025 at 21:16 UT ...

29.08.2025

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 26, 2025, Enveric Biosciences, Inc. (the "Company") received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it is not in compliance ...

29.08.2025

Enveric Biosciences Inc.

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Data establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for the ...

28.08.2025

Enveric Biosciences Inc.

Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q)

Management's discussion and analysis of financial condition and results of operations The information set forth below should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Unless stated otherwise, references in this Quarterly Report on Form 10-Q to "us," ...

14.08.2025

Enveric Biosciences Inc.

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric's differentiated neuroplastogen pipeline and IP platform. Q2 financial results were consistent with overall performance over the previous four quarters, and development costs were in line with ...

14.08.2025

Enveric Biosciences Inc. - news published 259 - readings 4.280

Enveric Biosciences Inc.

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Enveric Biosciences Inc.

Registration Statement - Specified Transactions (Form S-3)

Enveric Biosciences Inc.

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds (Form 8-K)

Enveric Biosciences Inc.

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Inc.

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Inc.

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Inc.

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences Inc.

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Inc.

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences Inc.

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA (Form 8-K)

Enveric Biosciences Inc.

Regulation FD Presentation (Form 8-K)

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule (Form 8-K)

Enveric Biosciences Inc.

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Inc.

Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q)

Enveric Biosciences Inc.

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member